澳大利亚男女校接种后青少年异性恋男性HPV感染率(2014-2017)
研究比较2014-2015与2016-2017两个时期17-19岁异性恋男性阴茎HPV感染率,以评估男性校接种项目实施效果。四价疫苗型别感染率两期均低(2.6% vs 0.7%),2016-2017期任意37型及13种高危型感染率呈下降趋势但无统计学意义;55%的后期招募者至少接种过一剂疫苗。
要点
- 四价疫苗型别感染率两期均低,推测女性接种计划产生群体保护。
- 2016-2017期任意37型HPV感染率为11.6%,低于2014-2015期的21.7%。
- 13种高危型感染率从15.8%降至7.5%,调整后患病率比0.59但无统计学意义。
核心结论
- 青少年异性恋男性四价疫苗型别HPV感染率在两个时期均低,可能源于女性接种计划的群体保护。
研究设计与样本
- 2014-2017年从澳大利亚性健康中心和社区招募17-19岁有性行为的异性恋男性,自我采集阴茎拭子检测37种HPV基因型。
- 2014-2015期招募152人,2016-2017期招募146人,比较两期HPV感染率,并核实自报疫苗接种剂次。
主要发现
- 四价疫苗型别(6/11/16/18)感染率2014-2015期为2.6%,2016-2017期为0.7%(p=0.371;aPR 0.28,95%CI 0.03-2.62)。
- 任意37种HPV基因型感染率2014-2015期为21.7%,2016-2017期为11.6%(aPR 0.62,95%CI 0.36-1.07)。
- 13种高危型HPV感染率2014-2015期为15.8%,2016-2017期为7.5%(aPR 0.59,95%CI 0.30-1.19)。
- 低危型HPV感染率两期无差异;2016-2017期招募者中55%至少接种过一剂疫苗。
临床怎么用
- 提示女性HPV疫苗接种可间接降低异性恋男性疫苗型别感染,支持群体免疫效应。
- 男性HPV感染监测应结合疫苗接种史和性行为因素进行动态评估。
局限性
- 两期HPV感染率差异无统计学意义,样本量有限。
- 需进一步研究确定普遍HPV疫苗接种对男性HPV感染率的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Australia introduced a school-based human papillomavirus (HPV) vaccination program for females aged 12-13 years in 2007, with a three-year catch-up to age 26; and for boys aged 12-13 from 2013, with a two-year catch-up to age 15. This study aimed to compare the prevalence of penile HPV between teenage heterosexual males in cohorts eligible or non-eligible for the school-based male vaccination program. METHODS: Between 2014 and 2017, sexually active heterosexual males aged 17-19 were recruited from sexual health centres and community sources across Australia. Males provided a self-collected penile swab for 37 HPV genotypes using Roche Linear Array and completed a questionnaire. We calculated adjusted prevalence ratios (aPR) of HPV between males in two periods: 2014-2015 (preceding implementation of school-based male vaccination) and 2016-2017 (eligible for school-based male vaccination). Self-reported vaccine doses were confirmed with doses reported to the National HPV Vaccination Program Register. RESULTS: Overall, 152 males were recruited in 2014-2015 and 146 in 2016-2017. Numbers of female sex partners and condom use did not differ between the two periods. The prevalence of quadrivalent vaccine-preventable [4vHPV] genotypes (6/11/16/18) was low in both periods (2.6% [2014-15] versus 0.7% [2016-17]; p = 0.371; aPR 0.28 [95% CI: 0.03-2.62]). Compared with men in 2014-2015, men in 2016-2017 had a lower prevalence of any of the 37 HPV genotypes tested (21.7% versus 11.6%; aPR 0.62 [95% CI: 0.36-1.07]) and any of the 13 high-risk genotypes tested (15.8% versus 7.5%; aPR 0.59 [95% CI: 0.30-1.19]). Prevalence of low-risk HPV genotypes did not differ between the two periods. Of the males recruited in 2016-2017, 55% had received ≥1 vaccine dose. CONCLUSION: The prevalence of 4vHPV genotypes among teenage heterosexual males in both cohorts was low, presumably due to herd protection from the female-only vaccination program. Further studies are required to determine the impact of universal HPV vaccination on HPV prevalence in males.
引用
- Chow EPF, Tabrizi SN, Fairley CK, et al. Prevalence of human papillomavirus in teenage heterosexual males following the implementation of female and male school-based vaccination in Australia: 2014-2017. Vaccine. 2019. PMID: 31562001. doi:10.1016/j.vaccine.2019.09.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。